In hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2−) BC patients, the decisions for adjuvant chemotherapy relies traditionally on tumor size, lymph node involvement, tumor grade, histologic type, and the Ki-67 proliferation index. The gene discussed is ERBB2; the disease is neoplasm.